Literature DB >> 25979197

A comparison of the efficacy of 70% v/v isopropyl alcohol with either 0.5% w/v or 2% w/v chlorhexidine gluconate for skin preparation before harvest of the long saphenous vein used in coronary artery bypass grafting.

Anna Casey1, Abdul Itrakjy2, Chrissie Birkett2, Alan Clethro2, Robert Bonser2, Tim Graham2, Jorge Mascaro2, Domenico Pagano2, Stephen Rooney2, Ian Wilson2, Peter Nightingale3, Cynthia Crosby4, Thomas Elliott5.   

Abstract

BACKGROUND: Chlorhexidine gluconate (CHG) is often recommended for skin antisepsis; however, the most efficacious concentration is currently unclear. Our objective was to compare the efficacy of 70% isopropyl alcohol (IPA) containing either 0.5% or 2% CHG for antiseptic skin preparation in patients undergoing coronary artery bypass grafting.
METHODS: One hundred patients were randomized to 1 of the 2 CHG concentrations. The designated antiseptic was applied to the skin of the operative site of patients before long saphenous vein harvest. Bacterial counts on the skin incision site were determined at various time points to assess any immediate and persistent antimicrobial activity. The number of patients developing surgical site infection was also determined.
RESULTS: The total numbers of microorganisms on the skin 2 minutes after skin antisepsis and after wound closure was lower with 2% CHG/70% IPA compared with 0.5% CHG/70% IPA (P = .033 and P = .016, respectively). Six of 41 patients in the 0.5% CHG/70%IPA group developed a superficial surgical site infection compared with 2 of 44 patients in the 2% CHG/70% IPA group (relative risk, 3.22; 95% confidence interval, 0.63-22.75; P = .147).
CONCLUSIONS: Isopropyl alcohol (70%) containing 2% CHG compared with 0.5% CHG reduces the number of microorganisms detectable on a surgical patient's skin perioperatively.
Copyright © 2015 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Skin antisepsis; Surgical site infection

Mesh:

Substances:

Year:  2015        PMID: 25979197     DOI: 10.1016/j.ajic.2015.03.034

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

1.  What's new in catheter-related infection: skin cleansing and skin antisepsis.

Authors:  Olivier Mimoz; Vineet Chopra; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-02-03       Impact factor: 17.440

Review 2.  Associated measures to antibiotic prophylaxis in urology.

Authors:  Franck Bruyere; Adrian Pilatz; Axelle Boehm; Benjamin Pradere; Florian Wagenlehner; Maxime Vallee
Journal:  World J Urol       Date:  2019-06-28       Impact factor: 4.226

3.  What's new in skin antisepsis for short-term intravascular catheters: new data to address old problems?

Authors:  Olivier Mimoz; Vineet Chopra; Andreas Widmer
Journal:  Intensive Care Med       Date:  2016-08-11       Impact factor: 17.440

4.  INSTRUMENT ASSISTED SOFT-TISSUE MOBILIZATION: A COMMENTARY ON CLINICAL PRACTICE GUIDELINES FOR REHABILITATION PROFESSIONALS.

Authors:  Scott W Cheatham; Russell Baker; Ethan Kreiswirth
Journal:  Int J Sports Phys Ther       Date:  2019-07

5.  Cluster-randomized crossover trial of chlorhexidine-alcohol versus iodine-alcohol for prevention of surgical-site infection (SKINFECT trial).

Authors:  A Charehbili; M B G Koek; J C A de Mol van Otterloo; M W G A Bronkhorst; P van der Zwaal; B Thomassen; E J Waasdorp; J A Govaert; A Bosman; J van den Bremer; A J Ploeg; H Putter; A P Meijs; C J H van de Velde; W van Gijn; R J Swijnenburg
Journal:  BJS Open       Date:  2019-05-20

6.  Efficacy of surgical skin preparation with chlorhexidine in alcohol according to the concentration required to prevent surgical site infection: meta-analysis.

Authors:  Tatsuki Hasegawa; Sho Tashiro; Takayuki Mihara; Junya Kon; Kazuki Sakurai; Yoko Tanaka; Takumi Morita; Yuki Enoki; Kazuaki Taguchi; Kazuaki Matsumoto; Kazuhiko Nakajima; Yoshio Takesue
Journal:  BJS Open       Date:  2022-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.